INhibiting mechanoTRansduction as a novel approach for Oncology theraPY (INTROPY)
This project aims to develop a first-in-class mechanoinhibitor drug targeting stiffness-induced protein unfolding in solid tumors, with potential applications in cancer therapy and fibrosis.
Projectdetails
Introduction
Increased tissue stiffness is a hallmark of many solid tumours, driving tumour progression. This occurs through mechanotransduction, the process by which cells sense and respond to mechanical signals.
Key Protein Interaction
Our lab has identified a key interaction between two proteins, essential for mechanotransduction. This interaction is triggered by force-induced unfolding of a target protein, which occurs only in stiff tissues.
Proposed Therapeutic Approach
Hence, we propose a novel therapeutic approach that targets mechanotransduction by inhibiting the stiffness-induced unfolding of the target protein. This innovative approach has the potential to transform cancer therapy and provide new insights into the role of mechanical signals in disease progression.
Methodology
We developed a thermal shift assay to identify molecules that stabilize the target and inhibit its unfolding. High throughput screening (HTS) of approximately 5,000 molecules resulted in 4 hits with confirmed specific binding by NMR analysis.
Additional Hits
Two additional hits were identified, each through structure-based virtual screening and a peptide-based approach, with confirmed binding through NMR analysis.
Project Aims
In this project, we aim to validate these 6 hits and to provide proof-of-concept evidence of their potential for cancer therapy.
Validation Steps
- In Vitro Validation: First, we will validate hits in vitro and in cellular assays.
- Optimization: Second, we will optimize them with medicinal chemists to obtain lead molecules.
- In Vivo Evaluation: Third, we will evaluate resulting lead molecules in an in vivo mouse breast cancer model.
Expected Outcomes
By the end of the project, we expect our data to be sufficient to attract private investment and establish a spin-off company to pursue drug development into clinical phases. This will lead to a first-in-class mechanoinhibitor drug, with potential applications in cancer (with a focus on breast and pancreatic cancer) and other conditions characterized by mechanical stress, such as fibrosis.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-8-2025 |
Einddatum | 31-1-2027 |
Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYApenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Personalised Mechanobiological Models to Predict Tumour Growth and Anti-Cancer Drug PenetrationThis project aims to develop a personalized cancer treatment framework by modeling stress-dependent tumor growth and drug penetration to enhance patient-specific therapy outcomes. | ERC Starting... | € 1.499.693 | 2024 | Details |
Mechanobiology of cancer progressionThis project aims to develop an innovative in vivo platform to study tumor fibrosis and improve targeted cancer therapies by mimicking the fibrotic microenvironment of breast cancer. | ERC Advanced... | € 2.498.690 | 2022 | Details |
Mechano-modulation of tumor microenvironment with mechanotherapeutics and sonopermeation to optimize nano-immunotherapyThis project aims to enhance drug delivery and treatment efficacy in desmoplastic tumors by synergistically combining mechanotherapeutics and ultrasound sonopermeation, supported by computational modeling. | ERC Starting... | € 1.500.000 | 2023 | Details |
Engineering soft microdevices for the mechanical characterization and stimulation of microtissuesThis project aims to advance mechanobiology by developing soft robotic micro-devices to study and manipulate 3D tissue responses, enhancing understanding of cell behavior and potential cancer treatments. | ERC Advanced... | € 3.475.660 | 2025 | Details |
Targeted Re-engineering of the Tumor Matrix to Advance ImmunotherapyThis project aims to disrupt the pro-fibrotic loop in pancreatic cancer using engineered biomimetics to enhance immune therapy efficacy by normalizing the tumor microenvironment. | ERC Advanced... | € 2.499.783 | 2024 | Details |
Personalised Mechanobiological Models to Predict Tumour Growth and Anti-Cancer Drug Penetration
This project aims to develop a personalized cancer treatment framework by modeling stress-dependent tumor growth and drug penetration to enhance patient-specific therapy outcomes.
Mechanobiology of cancer progression
This project aims to develop an innovative in vivo platform to study tumor fibrosis and improve targeted cancer therapies by mimicking the fibrotic microenvironment of breast cancer.
Mechano-modulation of tumor microenvironment with mechanotherapeutics and sonopermeation to optimize nano-immunotherapy
This project aims to enhance drug delivery and treatment efficacy in desmoplastic tumors by synergistically combining mechanotherapeutics and ultrasound sonopermeation, supported by computational modeling.
Engineering soft microdevices for the mechanical characterization and stimulation of microtissues
This project aims to advance mechanobiology by developing soft robotic micro-devices to study and manipulate 3D tissue responses, enhancing understanding of cell behavior and potential cancer treatments.
Targeted Re-engineering of the Tumor Matrix to Advance Immunotherapy
This project aims to disrupt the pro-fibrotic loop in pancreatic cancer using engineered biomimetics to enhance immune therapy efficacy by normalizing the tumor microenvironment.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.